Related Experiment Video
Updated: Jul 11, 2026

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022
[The yeast biofilm in human medicine]
Filip Růzicka1, Veronika Holá, Miroslav Votava
1Mikrobiologický ústav LF MU a FN u sv. Anny. fruzic@fnusa.cz
Abstract:
In recent years, the role of Candida yeasts as causative agents of nosocomial infections has increased. One of the important virulence factors contributing to the development of such infections is biofilm production. This virulence factor enables yeast to colonize both native surfaces and artificial implants. The most common sources of infection are patients themselves, in particular the gastrointestinal tract and skin. The vectors of exogenous yeast infections are predominantly the hands of the health personnel and contaminated medical instruments. The adhesion of yeasts to the implant surfaces is determined both by implant surface and yeast characteristics. This is followed by proliferation and production of microcolonies and extracellular matrix. The final biofilm structure is also influenced by the production of hyphae and pseudohyphae. The entire process of biofilm production is controlled by numerous regulatory systems, with the key role being played by the quorum sensing system. Like the adhered bacterial cultures, candidas growing in the form of a biofilm are highly resistant to antimicrobial therapy. Resistance of yeast biofilms to antifungals is a complex process with multiple contributing factors. These are especially increased gene expression (e.g. genes encoding the so called multidrug efflux pumps), limited penetration of substances through the extracellular matrix, inhibited cell growth and altered microenvironment in deeper biofilm layers. The concentrations of antifungals able to effectively affect the biofilm cells exceed, by several orders of magnitude, the values of conventionally determined MICs. High biofilm resistance results in ineffective antifungal therapy of biofilm infections. Therefore, if possible, the colonized implant should be removed. Conservative therapy should involve antifungals with a proven effect on the biofilm (e.g. caspofungin). The most effective measure in fighting biofilm infections is prevention, especially adhering to aseptic techniques when manipulating with implants and their correct maintenance.
Insights
Candida yeast biofilms cause difficult-to-treat nosocomial infections. These biofilms exhibit high antifungal resistance due to complex mechanisms, necessitating preventive strategies and specific treatments.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Microbial Pathogenesis
Background:
- Nosocomial infections caused by Candida yeasts are increasing.
- Biofilm production is a key virulence factor enabling yeast colonization of surfaces and implants.
- Infection sources include patients' gastrointestinal tract/skin, and contaminated medical instruments.
Purpose of the Study:
- To review the mechanisms of Candida biofilm formation and antifungal resistance.
- To discuss the challenges in treating biofilm-associated candidiasis.
- To highlight preventive measures and therapeutic strategies.
Main Methods:
- Literature review of Candida biofilm formation.
- Analysis of virulence factors and resistance mechanisms.
- Discussion of clinical implications and treatment options.
Main Results:
- Candida biofilms exhibit significant resistance to antifungals through mechanisms like increased efflux pump activity and altered microenvironments.
- Effective antifungal concentrations for biofilms far exceed standard MIC values.
- Implant removal and specific antifungals (e.g., caspofungin) are crucial for treatment.
Conclusions:
- Candida biofilm infections pose a significant therapeutic challenge due to high antifungal resistance.
- Prevention through aseptic techniques is paramount.
- Targeted antifungal therapy and, when necessary, implant removal are essential for managing these infections.
Related Concept Videos
Biofilms
Candidiasis
Yeast Signaling
Fungal Group Zygomycota

